Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00005096 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: docetaxel

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]